For emerging biopharma, CROs, CDMOs and pharma tech: senior marketers who understand MLR review, HCP audiences and long pharma sales cycles, without the overhead of a network agency.
Senior specialists, hourly billing you can see line by line, and a 30-day cancellation notice. Your first call is with a co-founder.
Medical, legal and regulatory reviewers sit between every draft and the market. In Vodori's 2025 benchmark, a video took 32 days on average to get approved, so a campaign planned without that time misses its window.
HCPs filter out anything that reads like an ad and listen to data and to each other. In a study of nearly 12,000 physicians, peer adoption strongly predicted who started prescribing a new drug.
A CRO or CDMO deal needs sign-off from R&D, procurement and quality. Each group reads your materials looking for a different risk, and one weak answer can stall the whole decision.
FDA's OPDP in the US, the ABPI Code in the UK and the EFPIA code across Europe each shape what you can claim, so one global campaign rarely runs unchanged in every market.
Together with your medical and regulatory team, we build a claims library that records every claim, its supporting reference and the channels it is cleared for. Templates are agreed with your reviewers up front, so review checks each asset against claims your team has already approved.
Content for physicians built on published data and the voices of their peers, plus a plan for the congresses that matter in your therapy area: abstracts, symposia, meetings booked in advance and follow-up content for the weeks after.
For CROs, CDMOs and pharma tech, we score target sponsors on pipeline, modality and outsourcing history, then reach R&D, procurement and quality with LinkedIn, content and BD outreach. Cradle reached scientists at top EU and US pharma companies this way.
Patient and site recruitment campaigns that stay within your protocol and ethics approvals: landing pages, prescreening forms and paid search and social, with each referral tracked to the site that received it.
Paid search, SEO and email run for a regulated category: approved claims only, platform healthcare ad policies checked before launch, and reporting your compliance team can audit line by line.
If a claim can't point to its reference, it never reaches your reviewers.
Both clients sell to scientific or clinical buyers, and every number here comes from their published case studies.
Every pharma client gets a separate plan, which your Head of Growth shapes around your modality, your sponsors and your review process. The cards show one example: a CDMO selling development and manufacturing services to biotech and pharma sponsors.
Buyer: brand and commercial teams at biopharma companies, and R&D, procurement and quality at sponsors. Proof: published data, approved claims and work for comparable sponsors.
Biotech and TechBio companies selling platforms and partnerships to pharma have their own page, built around scientific credibility and partnering.
Companies selling instruments, reagents and software to labs and CROs are covered on our life science page.
Our health tech report has a section on pharma as a buyer, drawn from James Eisner's experience selling to pharma companies: who holds the budget, why the digital health team is usually the way in, and what evidence gets a vendor considered.
Amsterdam and New York, for biopharma, CROs, CDMOs and pharma tech companies selling in Europe or the US.